Cargando…
Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up
BACKGROUND: Recent studies have reported atrial involvement and coexistence of aortic stenosis in transthyretin (ATTR) cardiac amyloidosis (CA). However, pathological reports of extraventricular ATTR amyloid deposits in atrial structures or heart valves are limited, and the clinical implications of...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234044/ https://www.ncbi.nlm.nih.gov/pubmed/37264308 http://dx.doi.org/10.1186/s12872-023-03319-3 |
_version_ | 1785052393283518464 |
---|---|
author | Okada, Atsushi Kakuta, Takashi Tadokoro, Naoki Tateishi, Emi Morita, Yoshiaki Kitai, Takeshi Amaki, Makoto Kanzaki, Hideaki Ohta-Ogo, Keiko Ikeda, Yoshihiko Fukushima, Satsuki Fujita, Tomoyuki Kusano, Kengo Noguchi, Teruo Izumi, Chisato |
author_facet | Okada, Atsushi Kakuta, Takashi Tadokoro, Naoki Tateishi, Emi Morita, Yoshiaki Kitai, Takeshi Amaki, Makoto Kanzaki, Hideaki Ohta-Ogo, Keiko Ikeda, Yoshihiko Fukushima, Satsuki Fujita, Tomoyuki Kusano, Kengo Noguchi, Teruo Izumi, Chisato |
author_sort | Okada, Atsushi |
collection | PubMed |
description | BACKGROUND: Recent studies have reported atrial involvement and coexistence of aortic stenosis in transthyretin (ATTR) cardiac amyloidosis (CA). However, pathological reports of extraventricular ATTR amyloid deposits in atrial structures or heart valves are limited, and the clinical implications of ATTR amyloid deposits outside the ventricles are not fully elucidated. CASE PRESENTATION: We report 3 cases of extraventricular ATTR amyloid deposits confirmed in surgically resected aortic valves and left atrial structures, all of which were unlikely to have significant ATTR amyloidosis infiltrating the ventricles as determined by multimodality evaluation including (99m)technetium-pyrophosphate scintigraphy, cardiac magnetic resonance, endomyocardial biopsy and their mid-term clinical course up to 5 years. These findings suggested that these were extraventricular ATTR amyloid deposits localized in the aortic valve and the left atrium. CONCLUSIONS: While long-term observation is required to fully clarify whether these extraventricular ATTR amyloid deposits are truly localized outside the ventricles or are early stages of ATTR-CA infiltrating the ventricles, our 3 cases with multimodality evaluations and mid-term follow up suggest the existence of extraventricular ATTR amyloid deposits localized in the aortic valve and left atrial structures. |
format | Online Article Text |
id | pubmed-10234044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102340442023-06-02 Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up Okada, Atsushi Kakuta, Takashi Tadokoro, Naoki Tateishi, Emi Morita, Yoshiaki Kitai, Takeshi Amaki, Makoto Kanzaki, Hideaki Ohta-Ogo, Keiko Ikeda, Yoshihiko Fukushima, Satsuki Fujita, Tomoyuki Kusano, Kengo Noguchi, Teruo Izumi, Chisato BMC Cardiovasc Disord Case Report BACKGROUND: Recent studies have reported atrial involvement and coexistence of aortic stenosis in transthyretin (ATTR) cardiac amyloidosis (CA). However, pathological reports of extraventricular ATTR amyloid deposits in atrial structures or heart valves are limited, and the clinical implications of ATTR amyloid deposits outside the ventricles are not fully elucidated. CASE PRESENTATION: We report 3 cases of extraventricular ATTR amyloid deposits confirmed in surgically resected aortic valves and left atrial structures, all of which were unlikely to have significant ATTR amyloidosis infiltrating the ventricles as determined by multimodality evaluation including (99m)technetium-pyrophosphate scintigraphy, cardiac magnetic resonance, endomyocardial biopsy and their mid-term clinical course up to 5 years. These findings suggested that these were extraventricular ATTR amyloid deposits localized in the aortic valve and the left atrium. CONCLUSIONS: While long-term observation is required to fully clarify whether these extraventricular ATTR amyloid deposits are truly localized outside the ventricles or are early stages of ATTR-CA infiltrating the ventricles, our 3 cases with multimodality evaluations and mid-term follow up suggest the existence of extraventricular ATTR amyloid deposits localized in the aortic valve and left atrial structures. BioMed Central 2023-06-01 /pmc/articles/PMC10234044/ /pubmed/37264308 http://dx.doi.org/10.1186/s12872-023-03319-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Okada, Atsushi Kakuta, Takashi Tadokoro, Naoki Tateishi, Emi Morita, Yoshiaki Kitai, Takeshi Amaki, Makoto Kanzaki, Hideaki Ohta-Ogo, Keiko Ikeda, Yoshihiko Fukushima, Satsuki Fujita, Tomoyuki Kusano, Kengo Noguchi, Teruo Izumi, Chisato Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up |
title | Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up |
title_full | Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up |
title_fullStr | Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up |
title_full_unstemmed | Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up |
title_short | Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up |
title_sort | transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234044/ https://www.ncbi.nlm.nih.gov/pubmed/37264308 http://dx.doi.org/10.1186/s12872-023-03319-3 |
work_keys_str_mv | AT okadaatsushi transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT kakutatakashi transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT tadokoronaoki transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT tateishiemi transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT moritayoshiaki transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT kitaitakeshi transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT amakimakoto transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT kanzakihideaki transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT ohtaogokeiko transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT ikedayoshihiko transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT fukushimasatsuki transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT fujitatomoyuki transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT kusanokengo transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT noguchiteruo transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup AT izumichisato transthyretinderivedamyloiddepositsintheatriumandtheaorticvalveinsightsfrommultimodalityevaluationsandmidtermfollowup |